
Adam J. Fein describes how the 340B program is being exploited by many hospital systems due to a lack of oversight by government agencies.
Adam J. Fein describes how the 340B program is being exploited by many hospital systems due to a lack of oversight by government agencies.
Einodshofer explains how the costs associated with one specialty patient's treatment can have the same financial footprint as an entire population of patients. Video from PBMI's Drug Benefit Conference 2013.
In this video from the 2013 Armada Specialty Pharmacy Summit in Las Vegas, Nevada, Adam J. Fein of Pembroke Consulting Inc and Drug Channels discusses the boom in new specialty pharmacy trade associations and describes the impact that competition amongst specialty pharmacy providers could have on the industry.
Troy Trygstad, PharmD, PhD, MBA, co-editor of the Directions in Pharmacy supplements, discusses the evolving health care landscape and how pharmacists can navigate it.
Colin Cooke, MD, discusses the role of the Affordable Care Act in expanding insurance coverage and in the formation of accountable care organizations.
Troy Trygstad, PharmD, PhD, MBA, discusses a flexible patient-centric approach to health care.
Timothy Ulbrich, PharmD, discusses the role of the pharmacist and how pharmacists are key to addressing our nation's medication crisis.
Troy Trygstad, PharmD, PhD, MBA, discusses emerging technology trends and how investments in technology will change health care.
Morgan Pharmacy in Washington, DC, has managed to keep its doors open for more than 100 years.
Troy Trygstad, PharmD, PhD, MBA, discusses the importance of the value-based model in health care and the perils and opportunities it poses to pharmacists.
In this video, executives from AstraZeneca and MedImmune explain why access to innovation in the development of biologics is so important.
Patrick Gleason, PharmD, BCPS, FCCP, director of Health Outcomes at Prime Therapeutics, discusses the value of pharmacogenomic testing and the factors that influence whether a health plan or PBM will reimburse for the use of that test.
Patrick Gleason, PharmD, BCPS, FCCP, director of health outcomes for Prime Therapeutics, explains how split-fill programs can help reduce waste for expensive specialty medications.
Jyoti Bhagia, MD, discusses use of a rating scale in diagnosing and treating patients with ADHD.
William A. Scott, MD, addresses the question of whether children who are initiating use of ADHD medication need to have an EKG.
Pediatrician Preeti Parikh, MD, provides an introduction to treatments for ADHD in children, including behavioral therapy, psychotherapy, family therapy, and various types of medication.
Peter Berger, MD, discusses the challenge of individualizing antiplatelet treatment for acute coronary syndrome patients.
A lecture on acute coronary syndromes by Kim A. Eagle, MD, director of the Cardiovascular Center at the University of Michigan Health System.
Jeffrey Berger, MD, discusses how research can help increase adherence to therapies among acute coronary syndrome patients.
A discussion of requirements for distributing medication guides when a drug is dispensed or distributed to a health care professional.
An animated video demonstrating how influenza virus enters a human cell, penetrates the nucleus, replicate itself, and emerges to infect other cells.
A discussion of high blood pressure and measures that can be taken to counter it, including prescription medication.
A discussion of efforts to develop a universal influenza vaccine that will be capable of protecting against any potential strain of the influenza virus.
Kurtis Reed, MD, discusses the results of his study on the incidence of melanoma among young adults.
This video from the National Institute of Allergy and Infectious Diseases discusses the causes of influenza pandemics.
Professor Dusheiko talks about managing HCV patients with cirrhosis.
Here, UCSF's Annie Luetkemeyer talks about new treatments for hepatitis C and what they will do for people with infections.
FHI 360 President Emeritus Ward Cates discusses the HIV treatment cascade. This model aims to bring us closer to the end of AIDS by addressing the gaps in the HIV diagnosis and treatment system currently in place.
Arun K. Ghosh. professor of organic and medicinal chemistry at Purdue University, talks with Hiroaki Mitsuya, Head of Experimental Retrovirology Section at the National Cancer Institute, about HIV drug development.
Dr. Paul Richardson discusses promising drugs in the pipeline for the treatment of myeloma and new combination treatments using older drugs.